BRIEF-Akero Therapeutics Presents New Phase 2b Trial Data On Efruxifermin At AASLD Liver Meeting 2025

Reuters11-07

BRIEF-<a href="https://laohu8.com/S/AKRO">Akero Therapeutics</a> Presents New Phase 2b Trial Data On Efruxifermin At AASLD Liver Meeting 2025

Nov 7 (Reuters) - Akero Therapeutics Inc AKRO.O:

AKERO THERAPEUTICS PRESENTS NEW ANALYSES FROM PHASE 2B SYMMETRY AND HARMONY TRIALS OF EFRUXIFERMIN AT 76TH ANNUAL AASLD THE LIVER MEETING® 2025

Source text: ID:nGNX2WgJ15

Further company coverage: AKRO.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2581000549?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-07 20:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581000549","market":"fut","top_or_hot":-1,"title":"BRIEF-Akero Therapeutics Presents New Phase 2b Trial Data On Efruxifermin At AASLD Liver Meeting 2025","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/AKRO\">Akero Therapeutics</a> Presents New Phase 2b Trial Data On Efruxifermin At AASLD Liver Meeting 2025</title></head><body><p><span>Nov 7 (Reuters)</span><span> - </span>Akero <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc <span>AKRO.O</span>:</p><ul><li><p>AKERO THERAPEUTICS PRESENTS NEW ANALYSES FROM PHASE 2B SYMMETRY AND HARMONY TRIALS OF EFRUXIFERMIN AT 76TH ANNUAL AASLD THE LIVER MEETING® 2025</p></li></ul><p>Source text: <span>ID:nGNX2WgJ15</span></p><p>Further company coverage: <span>AKRO.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Akero Therapeutics Presents New Phase 2b Trial Data On Efruxifermin At AASLD Liver Meeting 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Akero Therapeutics Presents New Phase 2b Trial Data On Efruxifermin At AASLD Liver Meeting 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-07 20:32</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/AKRO\">Akero Therapeutics</a> Presents New Phase 2b Trial Data On Efruxifermin At AASLD Liver Meeting 2025</title></head><body><p><span>Nov 7 (Reuters)</span><span> - </span>Akero <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc <span>AKRO.O</span>:</p><ul><li><p>AKERO THERAPEUTICS PRESENTS NEW ANALYSES FROM PHASE 2B SYMMETRY AND HARMONY TRIALS OF EFRUXIFERMIN AT 76TH ANNUAL AASLD THE LIVER MEETING® 2025</p></li></ul><p>Source text: <span>ID:nGNX2WgJ15</span></p><p>Further company coverage: <span>AKRO.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nTUABTJ0ML:1","article_id":"2581000549","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581000549","pubTimestamp":1762518745,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Akero Therapeutics Presents New Phase 2b Trial Data On Efruxifermin At AASLD Liver Meeting 2025Nov 7 (Reuters) - Akero Therapeutics Inc AKRO.O:AKERO THERAPEUTICS PRESENTS NEW ANALYSES FROM PHASE","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","AKRO":"Akero Therapeutics","BK4588":"碎股","BK4505":"高瓴资本持仓","BK4585":"ETF&股票定投概念"},"translate_title":"简介-Akero Therapeutics在2025年AASLD肝脏会议上展示了Efruxifermin的新2b期试验数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AKRO":0.9},"content_text":"BRIEF-Akero Therapeutics Presents New Phase 2b Trial Data On Efruxifermin At AASLD Liver Meeting 2025Nov 7 (Reuters) - Akero Therapeutics Inc AKRO.O:AKERO THERAPEUTICS PRESENTS NEW ANALYSES FROM PHASE 2B SYMMETRY AND HARMONY TRIALS OF EFRUXIFERMIN AT 76TH ANNUAL AASLD THE LIVER MEETING® 2025Source text: ID:nGNX2WgJ15Further company coverage: AKRO.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.10","shortVersion":"4.35.10","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2581000549","isCrawlerRequest":true}